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Abstract
Aims/hypothesis Chronic hyperglycaemia in type 1 diabetes affects the structure and functioning of the brain, but the impact of
recurrent hypoglycaemia is unclear. Changes in the neurochemical profile have been linked to loss of neuronal function. We
therefore aimed to investigate the impact of type 1 diabetes and burden of hypoglycaemia on brain metabolite levels, in which we
assumed the burden to be high in individuals with impaired awareness of hypoglycaemia (IAH) and low in those with normal
awareness of hypoglycaemia (NAH).
Methods We investigated 13 non-diabetic control participants, 18 individuals with type 1 diabetes and NAH and 13 individuals
with type 1 diabetes and IAH. Brain metabolite levels were determined by analysing previously obtained 1H magnetic resonance
spectroscopy data, measured under hyperinsulinaemic–euglycaemic conditions.
Results Brain glutamate levels were higher in participants with diabetes, both with NAH (+15%, p = 0.013) and with IAH
(+19%, p = 0.003), compared with control participants. Cerebral glutamate levels correlated with HbA1c levels (r = 0.40; p =
0.03) and correlated inversely (r = −0.36; p = 0.04) with the age at diagnosis of diabetes. Other metabolite levels did not differ
between groups, apart from an increase in aspartate in IAH.
Conclusions/interpretation In conclusion, brain glutamate levels are elevated in people with type 1 diabetes and correlate with
glycaemic control and age of disease diagnosis, but not with burden of hypoglycaemia as reflected by IAH. This suggests a
potential role for glutamate as an early marker of hyperglycaemia-induced cerebral complications of type 1 diabetes.
ClinicalTrials.gov NCT03286816; NCT02146404; NCT02308293
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Abbreviations
CRLB Cramér–Rao lower bound
CSF Cerebrospinal fluid
IAH Impaired awareness of hypoglycaemia
MAS Malate-aspartate shuttle
MRS Magnetic resonance spectroscopy
NAA N-acetylaspartate
NAAG N-acetylaspartylglutamate
NAH Normal awareness of hypoglycaemia
SNR Signal-to-noise ratio
TCA Tricarboxylic acid
TE Echo time
TR Repetition time
Introduction
Type 1 diabetes has a negative effect on the structure and
functioning of the brain [1]. Several studies report on a lower
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cognitive performance in people with type 1 diabetes com-
pared with non-diabetic individuals, particularly regarding
memory function and learning [2–4]. Structural cerebral
changes, such as a reduced grey matter volume, have also
been described in type 1 diabetes [5–7]. Moreover, it is known
that type 1 diabetes affects cerebral metabolism and metabolic
pathways [8], especially in response to acute hypoglycaemia
[9]. Known risk factors for these structural and functional
effects on the brain include diabetes onset in early childhood
[10, 11] and poor glycaemic control [12]. Recently, the pres-
ence of impaired awareness of hypoglycaemia (IAH), which
results from exposure to recurrent hypoglycaemia, has also
been associated with reduced cognitive function [13] and
structural cerebral decline [5]. The neurochemical mecha-
nism(s) that may precede, underlie or accompany these effects
on the brain are not well studied, hence elucidation of such
mechanism may provide further insight into detrimental ef-
fects of type 1 diabetes on the brain.
1H MR spectroscopy (MRS) is a suitable tool for the non-
invasive examination of a range of neuro-metabolites in
humans [14]. Previous studies using 1H MRS have suggested
that a change in brain glutamate may have a role in neuronal
function loss in type 1 diabetes. Under hyperglycaemic con-
ditions, the levels of glutamate and N-acetylaspartate (NAA)
were lower in individuals with long-term type 1 diabetes com-
pared with non-diabetic control participants [15]. Since NAA
and glutamate are metabolites that mainly reside in neurons,
these lower levels were attributed to a loss of neuronal func-
tion. However, such lower levels were not found when
individuals were studied under euglycaemic conditions [16].
Moreover, in a large cohort, an increase in prefrontal gluta-
mate levels in type 1 diabetes was described, with a linear
relation between glutamate levels and lifetime glycaemic con-
trol [4]. The impact of recurrent hypoglycaemia on brain me-
tabolite levels is currently not known.
Using IAH as a proxy for significant burden of
hypoglycaemia, we aimed to assess the impact of recurrent
hypoglycaemia on brain metabolites as measured by 1H MRS
by comparing these in individuals with type 1 diabetes mellitus
and IAH to those with normal awareness of hypoglycaemia
(NAH) and non-diabetic control participants. Furthermore, we
aimed to evaluate the effect of potential mediators for structural
and functional cerebral decline, such as level of glycaemic con-
trol and age at diagnosis, on metabolites in the brain.
Methods
The 1H MRS data were acquired as part of three previously
conducted studies [17–19], focusing on cerebral lactate levels
during euglycaemia and hypoglycaemia, using the
hyperinsulinaemic clamp technique. Here we analysed the
total neurochemical profile of the participants as seen by 1H
MRS, recorded under hyperinsulinaemic–euglycaemic condi-
tions. These data had not been previously analysed. Details
regarding the hyperinsulinaemic glucose clamp have been re-
ported previously [17–19]. Participants were not subjected to
any intervention other than the hyperinsulinaemic–
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euglycaemic clamp during data acquisition. All data were ac-
quired between September 2014 and August 2017 and all
participants gave written informed consent. The studies were
approved by and studied in accordance with the ethical stan-
dards of the institutional review board of the Radboud univer-
sity medical center (Commissie Mensgebonden Onderzoek
Arnhem-Nijmegen) and with the Declaration of Helsinki of
1975/1983 and its later amendments and revisions.
The cohort consisted of 13 individuals without diabetes, 18
with type 1 diabetes and NAH, and 13 with type 1 diabetes and
IAH. Participants with type 1 diabetes were initially classified
as NAH or IAH using the Dutch modified version of the Cox
questionnaire [20, 21], and their state of awareness was retro-
spectively confirmed during clamped hypoglycaemia on the
basis of adrenaline and hypoglycaemic symptom responses.
HbA1c levels of the individuals with type 1 diabetes were de-
termined at the time of inclusion. Participants with type 1 dia-
betes were further subdivided into those with optimal
glycaemic control (i.e. HbA1c <53 mmol/mol [7.0%]) and sub-
optimal glycaemic control (i.e., HbA1c ≥53 mmol/mol [7.0%]).
Main exclusion criteria were: MRI contraindications, the use of
drugs (other than insulin) that may alter glucose metabolism,
HbA1c levels >75 mmol/mol (9.0%) and presence of microvas-
cular complications, except for background retinopathy.
MRS protocol and data processing
MRSmeasurements were performed on a 3TMR system (Tim
MAGNETOMTrio (n = 32) orMAGNETOMPrisma-fit (n =
12), Siemens, Erlangen, Germany), using a body coil for ex-
citation and a 12-channel receive-only head coil. AT1-weight-
ed anatomical image (MPRAGE; 256 × 256 mm2 field of
view; 1 mm3 isotropic voxels) was used for MRS voxel posi-
tioning and for determination of the amount of grey matter,
white matter and cerebrospinal fluid (CSF) in the MRS voxel.
1H MRS data were acquired from a single voxel (22.5–
25.0 cm3) in the periventricular region of the brain. A semi-
LASER spectroscopy sequence [22] was used with an 8-step
phase cycle and an echo time (TE) of 30 ms (Trio) or 33 ms
(Prisma-fit), a repetition time (TR) of 3000 ms and 32 aver-
ages, combined with WETwater suppression (water suppres-
sion enhanced through T1 effects) [23]. Awater-unsuppressed
spectrum was acquired for each participant from the same
voxel with a TR of 5000 ms, a TE of 30 or 33 ms and 4
averages, used for eddy-current correction and for absolute
metabolite quantification.
Spectra were analysed with LCModel software [24]. The
LCModel basis set, one for each TE, was created in Bruker
TopSpin (Bruker, Billerica, MA, USA) and contained 19 metab-
olites: Ala, Asp, choline, creatine,γ-aminobutyric acid (GABA),
glucose, Glu, Gln, glutathione, glycerophosphocholine, Gly, lac-
tate, myo-inositol, NAA, N-acetylaspartylglutamate (NAAG),
phosphocholine, phosphocreatine, scyllo-inositol and taurine.
The basis set was extended with a previously measured mac-
romolecular baseline [25]. The spectral region between 0.5 and
4.2 ppm was used in the LCModel analysis. Metabolites
quantified with a Cramér–Rao lower bound (CRLB) >50%
were classified as undetected and only metabolites quantified
with a CRLB <50% in at least half of the spectra were used in
the analysis. The CRLB cut-off of 50% was chosen to avoid
direct rejection ofmetabolites with a low concentration [26]. If
the covariance between metabolites was consistently high
(i.e., r below −0.3), the sum of the related metabolites was
reported; this was the case for total NAA (NAA + NAAG),
total choline (phosphocholine + glycerophosphocholine) and
total creatine (creatine + phosphocreatine), but not for Glu +
Gln (mean r: 0.02 ± 0.14). The signal-to-noise ratio (SNR)
and spectral linewidths were analysed in the context of quality
assessment. SNR was defined as the ratio of the maximum
height of the largest signal (i.e., NAA) to twice the root-
mean-square of the noise and the spectral linewidth as the full
width at half-maximum of the respective water-unsuppressed
spectrum. The SNR and linewidths were reported by
LCModel.
To determine the relative proportions of grey matter, white
matter and CSF in theMRS voxel, we segmented the T1-weight-
ed images usingMatlab 2017b (MathWorks, Natick,MA, USA)
and the VBM8 toolbox in SPM8 (Functional Imaging
Laboratory, University College London, London, UK). These
fractions were used to estimate the water content in the MRS
voxel, assuming a water concentration of 43.3 mol/l in grey
matter, 35.9 mol/l in white matter and 55.6 mol/l in CSF [27],
and to correct for partial volume effects [28]. Concentrations
were also corrected for T1 and T2 relaxation.
Statistical analysis Differences in metabolite levels between
individuals with IAH, those with NAH and non-diabetic con-
trol participants were determined using ANOVA with
Bonferroni post hoc tests to accommodate the three groups
design. Analyses were repeated using ANCOVA to adjust
comparisons for voxel content (i.e., the amount of grey matter
in the voxel). ANOVA and ANCOVA results were similar;
therefore only those calculated using ANOVA are reported.
Linear regression analysis was performed between gluta-
mate levels and HbA1c levels and between glutamate levels
and the age at diagnosis of diabetes. In a secondary analysis
we subdivided the participants into those with optimal or sub-
optimal glycaemic control. ANOVAs were conducted to de-
tect differences between non-diabetic individuals, individuals
with NAH and optimal glycaemic control (mean HbA1c: 48.2
± 2.9 mmol/mol [6.5 ± 0.3%], n = 6), those with NAH and
suboptimal glycaemic control (59.7 ± 4.8 mmol/mol [7.6 ±
0.4%), n = 12], those with IAH and optimal glycaemic control
(47.6 ± 7.7 mmol/mol [6.5 ± 0.7%], n = 5) and those with IAH
and suboptimal glycaemic control (58.6 ± 4.9 mmol/mol [7.5
± 0.4%], n = 8).
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Data are presented as mean ± SD. All statistical analyses
were performed in IBMSPSS Statistics 22 (IBM, Chicago, IL,
USA). A p value less than 0.05 was considered statistically
significant. No correction for multiple comparisons was
performed.
Results
The participants were matched for age, sex and BMI, and for
diabetes duration and HbA1c levels in the patient groups
(Table 1). There were also no significant differences in these
variables (except for HbA1c levels) between the subgroups of
participants subdivided according to glycaemic control (data
not shown). Plasma glucose levels were well in the
euglycaemic range during the acquisition of the MRS data,
with no differences between groups (overall mean: 5.3 ±
0.6 mmol/l and a mean CVof 10.6%).
The 1H MR spectra were of good quality (see Fig. 1), with
comparable linewidths (overall mean: 0.05 ± 0.01 ppm) and
SNR (overall mean: 39.7 ± 7.9) between groups. The MRS
voxel contained on average ~65–70% (parietal) white matter,
with no differences in voxel composition between groups
(Table 2).
Ten metabolites were consistently quantified using
LCModel. Mean CRLBs were <10% for Glu, glutathione,
myo-inositol, total creatine, total choline and tNAA and
<30% for Asp, Gln, scyllo-inositol and taurine (Table 3).
Brain glutamate levels were significantly higher in individ-
uals with type 1 diabetes, both in those with NAH (+15%, p =
0.013) and in those with IAH (+19%, p = 0.003), when com-
pared with non-diabetic control participants. Glutamate levels
did not differ between the two patient subgroups (p = 1.0).
Furthermore, we observed higher aspartate levels in type 1 dia-
betes and IAH (+30%, p = 0.009) compared with non-diabetic
control participants. All other metabolite levels, as well as the
level of macromolecules, were similar across groups (Fig. 2).
Cerebral glutamate levels were linearly correlated to HbA1c
levels in individuals with type 1 diabetes (p = 0.03; r = 0.40;
Fig. 3a) and inversely correlated to the age at diagnosis of
diabetes (p = 0.04; r = −0.36; Fig. 3b). The variance inflation
factor (VIF) between both predictors was 1.19, meaning that
there was no noteworthy collinearity within our data. A sen-
sitivity analysis excluding outliers did not materially change
these associations. There was no correlation between cerebral
glutamate levels and the duration of type 1 diabetes.
Subdividing the participants into those with optimal or subop-
timal glycaemic control gave further insight into the elevated
cerebral glutamate levels. Cerebral glutamate levels were par-
ticularly elevated in participants with suboptimal glycaemic
control, and particularly in those with IAH (Fig. 4). There
were no differences in glutamate levels between both sub-
groups of individuals with optimal glycaemic control and
non-diabetic individuals (Fig. 4). There was no difference be-
tween male and female participants.
Discussion
Here we evaluated the neurochemical profile of participants
with type 1 diabetes, with and without IAH, under
euglycaemic conditions and compared this with non-diabetic
control participants. Our main finding was that brain gluta-
mate levels are elevated in both groups of participants with
diabetes compared with healthy non-diabetic control partici-
pants. Known risk factors for functional and structural cere-
bral decline in type 1 diabetes, i.e. glycaemic control and an
early age of disease onset, are correlated to these elevated
glutamate levels. The presence or absence of IAH did not
affect glutamate levels.
Glutamate is one of the most important excitatory neuro-
transmitters and studies have shown that increased glutamate
levels are roughly linearly related with increased excitatory
activity [29]. Therefore, changes in glutamate levels have
been linked to metabolic activity [29, 30]. The greater cerebral
glutamate levels in people with type 1 diabetes as compared
with those without diabetes could be interpreted as an upreg-
ulation of cerebral metabolism in individuals with type 1 dia-
betes. However, this contrasts with studies that reported no
significant difference in the tricarboxylic acid (TCA) cycle
Table 1 Participant
characteristics Variable Non-diabetic control (n = 13) T1DM NAH (n = 18) T1DM IAH (n = 13)
Age (years) 25.5 ± 5.5 25.3 ± 7.2 26.1 ± 6.8
Sex (male/female) 6 / 7 10 / 8 7 / 6
BMI (kg/m2) 23.5 ± 1.6 24.0 ± 2.6 23.7 ± 1.5
Duration of T1DM (years) 11.4 ± 6.8 14.1 ± 9.3
HbA1c (mmol/mol) 55.8 ± 6.9 54.4 ± 8.0
HbA1c (%) 7.3 ± 0.6 7.1 ± 0.7
Data are presented as number or mean ± SD
T1DM IAH, type 1 diabetes with IAH; T1DM NAH, type 1 diabetes with NAH
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rate during euglycaemia between individuals with type 1 dia-
betes and non-diabetic control participants [31]. Alternatively,
glutamate itself may act as a metabolic substrate for the TCA
cycle, through conversion to α-ketoglutarate. Previous studies
have shown that cerebral glutamate levels drop in response to
acute hypoglycaemia in individuals with type 1 diabetes with
intact hormonal responses to hypoglycaemia, which was at-
tributed to glutamate acting as an alternative fuel [18, 19, 32].
Glutamate oxidation can complement glucose use [33]. The
higher glutamate levels could be the result of a cerebral pro-
tection mechanism in response to multiple hypoglycaemic
insults, and thus cerebral glucose deprivation, during a life-
time with diabetes. Finally, elevated extracellular glutamate
levels are known to be excitotoxic, which triggers various
processes that result in neuronal cell death. Glutamate
excitotoxicty is thought to be involved in neurodegenerative
diseases such as Parkinson’s disease and Huntington’s disease
[34], which also show higher cerebral glutamate levels [35].
However, since the extracellular level of glutamate in the brain
is only a few μmol/l, it is not expected to be detected by 1H
MRS.
Our results are in line with a large cohort study in which
elevated prefrontal glutamate levels were found in individuals
with long-standing type 1 diabetes [4]. These higher glutamate
concentrations were associated with lower cognitive function
as well as with mild depression, and correlated with lifetime
glycaemic control. Here we show that another risk factor for
cerebral decline, namely the age of onset of diabetes, also
correlated with cerebral glutamate levels. These findings indi-
cate that elevated brain glutamate may be an early marker of
the potentially devastating effect of chronic hyperglycaemia,
in particular on the developing brain. The presence of IAH
alone has only limited additional consequences regarding ce-
rebral glutamate levels. Interestingly, glutamate levels were
the highest, although this difference was not significant, in
individuals with both IAH and suboptimal HbA1C levels,
which may suggest that individuals with the most fluctuating
glucose levels are more prone to these alterations.
Our data contrasts with a 1H MRS study that showed a
decline in cerebral glutamate levels in people with type 1
diabetes [15]. In that study, however, data were acquired dur-
ing a hyperglycaemic clamp, which may have altered cerebral
metabolism [36, 37]. Furthermore, these lower glutamate
levels were only found in a grey-matter-rich voxel and not in
a white-matter-rich region as studied here, suggestive of
region-specific metabolic alterations, as also described in a
rat model of type 1 diabetes [38].
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Fig. 1 Example of LCModel analysis of one 1H MR spectrum (top row).
The peaks identified include macromolecules (MM), aspartate (Asp),
creatine (Cre), glutamine (Gln), glutamate (Glu), glycerophosphocholine
(GPC), glutathione (GSH), myo-inositol (mI), N-acetylaspartate (NAA),
N-acetylaspartylglutamate (NAAG), phosphocholine (PCh), phosphocre-
atine (PCr), scyllo-inositol (Scyllo) and taurine (Tau). The insert shows
the localisation of the MRS voxel
Table 2 SNR, linewidths and
voxel composition Variable Non-diabetic control T1DM NAH T1DM IAH p value
SNR 41.2 ± 6.9 40.5 ± 7.3 36.9 ± 9.5 0.34
Linewidth (ppm) [Hz] 0.05 ± 0.01 [6.5 ± 1.4] 0.05 ± 0.01 [6.3 ± 0.9] 0.05 ± 0.01 [6.0 ± 0.9] 0.54
Grey matter (%) 26.5 ± 4.2 29.5 ± 6.0 31.1 ± 6.3 0.12
White matter (%) 71.3 ± 4.7 67.6 ± 6.9 66.0 ± 7.1 0.11
CSF (%) 2.2 ± 0.9 2.9 ± 1.3 3.1 ± 1.4 0.18
Data are presented as number or mean ± SD
T1DM IAH, type 1 diabetes with IAH; T1DM NAH, type 1 diabetes with NAH
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We also found increased aspartate levels in participants
with IAH compared with non-diabetic control participants.
Aspartate, like glutamate, is an excitatory neurotransmitter
and both are synthesised from glucose in the brain.
Aspartate and glutamate are also linked through the malate-
aspartate shuttle (MAS). However, an increased flux through
the MAS implies opposite changes in glutamate and aspartate
levels [30], which is not in line with our results.
Our finding of increased glutamate levels in the brain of
individuals with type 1 diabetes is also important in the con-
text of studies on brain metabolism with 13C MRS and meta-
bolic modelling. Brain glutamate levels are typically used as
an input in such models and often it is assumed that glutamate
levels are constant (e.g. no change upon hypoglycaemia) and
not different between different groups of individuals (e.g. no
difference between individuals with and without diabetes) [31,
39]. These assumptions are critical and deviations may have a
significant impact on outcomes. The results of the current
study presents an argument for using measured glutamate
levels as input in such models.
The present study has some limitations. MRS data were
acquired from a large single voxel, which precludes any anal-
ysis of the regional dependency of the described alterations.
Furthermore, we performed an explorative analysis on multi-
ple metabolites in a rather limited sample size. As a conse-
quence of clamp conditions, insulin levels were elevated albeit
within the physiological range. We are, however, unaware of
modulating effects of insulin on brain glutamate levels.
Furthermore, we used the presence of IAH as proxy for recur-
rent hypoglycaemia, since habituation to frequent
hypoglycaemia underlies the pathogenesis of IAH. We ac-
knowledge that IAH is not an on/off phenomenon, so an
Table 3 Quantification results
Metabolite
Asp Gln Glu GSH mI Scyllo Tau tCho tCre tNAA MM
Healthy control participants
Mean (μmol/g, ww) 2.07 1.32 6.10 0.94 5.51 0.57 1.74 1.79 6.94 11.12 48.30
SD (μmol/g, ww) 0.34 0.44 0.74 0.12 0.79 0.17 0.50 0.16 0.41 0.55 9.36
Mean CRLB (%) 20.9 26.8 5.5 8.4 4.5 17.1 17.2 3.8 2.0 1.7 11.6
SD CRLB (%) 4.9 6.7 0.9 1.0 1.1 5.9 6.0 2.5 0.0 0.4 3.5
n 13 12 13 13 13 13 12 13 13 13 13
Type 1 diabetes and NAH
Mean (μmol/g, ww) 2.26 1.45 7.04 1.02 5.45 0.41 1.98 1.90 6.92 10.74 45.10
SD (μmol/g, ww) 0.51 0.57 0.86 0.13 1.09 0.13 0.54 0.39 0.51 0.58 7.20
Mean CRLB (%) 20.8 27.2 5.1 8.6 4.8 23.7 17.7 3.3 2.0 1.7 13.1
SD CRLB (%) 8.8 8.9 0.8 1.6 2.0 6.5 6.7 1.6 0.0 0.5 3.7
n 17 18 18 18 18 17 17 18 18 18 18
Type 1 diabetes and IAH
Mean (μmol/g, ww) 2.70 1.64 7.29 1.22 5.86 0.45 1.63 1.97 7.07 10.98 48.29
SD (μmol/g, ww) 0.61 0.68 0.93 0.57 0.93 0.18 0.39 0.31 0.44 0.46 14.31
Mean CRLB (%) 18.2 25.2 5.5 8.5 4.4 24.1 24.1 3.8 2.1 1.9 13.5
SD CRLB (%) 5.1 6.7 1.2 2.4 1.3 8.2 8.2 3.0 0.4 0.6 8.0
n 13 13 13 13 13 12 13 13 13 13 13
GSH, glutathione; mI, myo-Inositol; MM, macromolecules; Scyllo, scyllo-inositol; Tau, taurine; tCho, total choline; tCre, total creatine; tNAA, total
NAA; ww, wet weight
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Fig. 2 Mean metabolite levels in participants with type 1 diabetes and
IAH (T1DM IAH), participants with type 1 diabetes and NAH (T1DM
NAH) and non-diabetic control participants. Between group differences
were assessed with ANOVAwith Bonferroni post hoc tests to accommo-
date the three groups design; *p < 0.05. Data are mean + SD, with indi-
vidual data points shown as dots. GSH, glutathione; mI, myo-inositol;
MM, macromolecules; Scyllo, scyllo-inositol; Tau, taurine; tCho, total
choline; tCre, total creatine; tNAA, total NAA; ww, wet weight
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impact of hypoglycaemia, which also occurs in individuals
with NAH, cannot be fully excluded. Also, we did not actually
measure burden of hypoglycaemia, but based on the patho-
genesis of IAHwe assumed this burden to be greater in people
with IAH than in those with NAH. Finally, inherent to the
inclusion criteria, the participants with type 1 diabetes all
had HbA1c levels below 9.0% and were relatively young.
Future research should focus on the effect of more poorly
controlled and long-standing diabetes.
In conclusion, we show that there are alterations in neuro-
metabolites in individuals with type 1 diabetes. Cerebral glu-
tamate levels are higher in type 1 diabetes and correlate with
known risk factors for cerebral decline, suggesting a potential
role for glutamate as an early indicator of cerebral complica-
tions of type 1 diabetes. The presence of IAH, which usually
results from recurrent hypoglycaemia, has only limited
additional impact on the neurochemical profile of individuals
with type 1 diabetes.
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NAH (T1DMNAH; black circles), together with the linear fits of the data
and the 95% CI, obtained from linear regression analysis. (a) p = 0.03;
r = 0.40; (b) p = 0.04; r = −0.36; ww, wet weight
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Fig. 4 Cerebral glutamate levels. Group means are depicted in black
circles. Participants with type 1 diabetes are further subdivided into those
with optimal glycaemic control (HbA1c <53 mmol/mol [7.0%]) and those
with suboptimal glycaemic control (HbA1c ≥53 mmol/mol). ANOVAs
were conducted to detect differences among non-diabetic individuals,
and diabetic individuals with NAH and optimal glycaemic control,
NAH and suboptimal glycaemic control, IAH and optimal glycaemic
control, and IAH and suboptimal glycaemic control; *p < 0.05,
**p < 0.01 vs non-diabetic control participants. ND, non-diabetic control;
T1DM, type 1 diabetes; ww, wet weight
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